Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update

Kronos Bio, Inc. (NASDAQ:KRON) saw a large decrease in short interest in July. As of July 31st, there was short interest totalling 718,500 shares, a decrease of 7.8% from the July 15th total of 779,500 shares. Based on an average daily trading volume, of 381,300 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.9% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $2.25 target price on shares of Kronos Bio in a research report on Monday.

Insider Buying and Selling at Kronos Bio

In other news, CEO Norbert W. Bischofberger purchased 1,378,901 shares of the stock in a transaction dated Monday, June 10th. The shares were purchased at an average price of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now owns 5,749,395 shares in the company, valued at approximately $5,059,467.60. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Norbert W. Bischofberger purchased 1,378,901 shares of Kronos Bio stock in a transaction dated Monday, June 10th. The shares were purchased at an average price of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now owns 5,749,395 shares in the company, valued at $5,059,467.60. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Norbert W. Bischofberger bought 881,913 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average cost of $1.24 per share, with a total value of $1,093,572.12. Following the purchase, the chief executive officer now owns 7,375,616 shares of the company’s stock, valued at $9,145,763.84. The disclosure for this purchase can be found here. Insiders purchased a total of 2,671,662 shares of company stock worth $2,787,697 in the last three months. 23.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KRON. Virtu Financial LLC purchased a new position in Kronos Bio in the 1st quarter valued at approximately $71,000. Marquette Asset Management LLC grew its stake in Kronos Bio by 19.8% in the 1st quarter. Marquette Asset Management LLC now owns 80,369 shares of the company’s stock valued at $104,000 after acquiring an additional 13,269 shares during the last quarter. Forefront Analytics LLC increased its holdings in Kronos Bio by 75.0% during the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock valued at $167,000 after acquiring an additional 57,867 shares in the last quarter. Cerity Partners LLC purchased a new position in Kronos Bio during the 4th quarter valued at about $513,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Kronos Bio by 17.2% in the first quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock valued at $1,005,000 after purchasing an additional 113,618 shares in the last quarter. 64.09% of the stock is currently owned by institutional investors and hedge funds.

Kronos Bio Price Performance

KRON opened at $1.00 on Wednesday. The business has a fifty day moving average price of $1.17 and a 200 day moving average price of $1.10. Kronos Bio has a 12 month low of $0.69 and a 12 month high of $1.60. The stock has a market capitalization of $60.09 million, a price-to-earnings ratio of -0.50 and a beta of 1.89.

Kronos Bio (NASDAQ:KRON) last posted its earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The business had revenue of $2.69 million for the quarter, compared to analysts’ expectations of $1.75 million. Kronos Bio had a negative return on equity of 68.67% and a negative net margin of 1,534.11%. On average, research analysts anticipate that Kronos Bio will post -1.62 earnings per share for the current year.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.